Serum sFlt1:PlGF Ratio, PlGF, and Soluble Endoglin Levels in Gestational Proteinuria

REFERENCES

• Sato K. A proposal for a new definition and classification of “Pregnancy induced Hypertension (PIH)” (2004). in Japan Society for the Study of Toxemia of Pregnancy (ed): Historical Perspective of Study of Pregnancy-Induced Hypertension in Japan. Medical View Co, Tokyo 2005; 54–87
   Google Scholar
• Davison JM. The effect of pregnancy on kidney function in renal allograft recipients. Kidney Int 1985; 27: 74–79
   Google Scholar
• Higby K, Suiter CR, Phelps JY, Siler-Khodr T, Langer O. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 1994; 171: 984–989
   PubMed Web of Science ®Google Scholar
• Gordon M, Landon MB, Samuels P, Hissrich S, Gabbe SG. Perinatal outcome and long-term follow-up associated with modern management of diabetic nephropathy. Obstet Gynecol 1996; 87: 401–409
   PubMed Web of Science ®Google Scholar
• Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1–S22
   PubMed Web of Science ®Google Scholar
• Helewa ME, Burrows RF, Smith J, Williams K, Brain P, Rabkin SW. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157: 715–725
   PubMed Web of Science ®Google Scholar
• Brown MA, Hague WM, Higgins J, et al. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol 2000; 40: 139–155
   PubMed Web of Science ®Google Scholar
• Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX–XIV
   PubMed Web of Science ®Google Scholar
• Hidaka A, Nakamoto O, Eguchi K, Furuhashi N, Yamaguchi K. Juushou ninshin tyuudokushou to gappeishou: Juushou ninshin tyuudokushou case card tyousa No. 3 (Maternal complications in toxemia of pregnancy: Case analysis of women with severe toxemia in pregnancy, the 3rd report). Journal of Japan Society for the Study of Toxemia of Pregnancy 1998; 6: 174–182
   Google Scholar
• Hidaka A, Nakamoto O, Eguchi K, Furuhashi N, Yamaguchi K. Juushou ninsin tyuudokushou to taiji hatsuiku syougai: Juushou ninsin tyuudokusyou case card tyousa No. 4 (Intrauterine growth retardation in toxemia of pregnancy: Case analysis of women with severe toxemia in pregnancy, the 4th report). Journal of Japan Society for the Study of Toxemia of Pregnancy 1998; 6: 183–193
   Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12: 642–649
   PubMed Web of Science ®Google Scholar
• Gougos A, St Jacques S, Greaves A, et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992; 4: 83–92
   PubMed Web of Science ®Google Scholar
• Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 2005; 96: 684–692
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005
   PubMed Web of Science ®Google Scholar
• Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 2006; 194: 551–556
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Arai F, et al. Establishing reference values for both total soluble Fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 2005; 28: 727–732
   PubMed Web of Science ®Google Scholar
• Hirashima C, Ohkuchi A, Matsubara S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early onset preeclampsia compared to late onset preeclampsia. Hypertens Res 2008, 31: 1541–1548
   Google Scholar
• Ohkuchi A, Hirashima C, Matsubara S, et al. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30: 151–159
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Iwamura T, Kuriya N, et al. Birth size standards by gestational age for Japanese neonates. Acta Neonatologica Japonica 1998; 34: 624–632
   Google Scholar
• Stettler RW, Cunningham FG. Natural history of chronic proteinuria complicating pregnancy. Am J Obstet Gynecol 1992; 167: 1219–1224
   PubMed Web of Science ®Google Scholar
• Morikawa M, Yamada T, Yamada T, et al. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation [published online ahead of print Jun 12, 2008]. J Perinat Med, doi: 10.1515/JPM.2008.062
   Google Scholar
• Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658
   PubMed Web of Science ®Google Scholar
• Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003; 188: 177–182
   PubMed Web of Science ®Google Scholar
• Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267–1272
   PubMed Web of Science ®Google Scholar
• Chappell LC, Seed PT, Briley A, et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol 2002; 187: 127–136
   PubMed Web of Science ®Google Scholar
• Livingston JC, Haddad B, Gorski LA, et al. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol 2001; 184: 1218–1220
   PubMed Web of Science ®Google Scholar
• Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101–111
   PubMed Web of Science ®Google Scholar
• Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res 2008; 75: 1–8
   PubMed Web of Science ®Google Scholar